- Home
- IREN vs NAMS Comparison
IREN vs NAMS Comparison
Compare IREN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IREN
- NAMS
- Stock Information
- Founded
- IREN 2018
- NAMS 2019
- Country
- IREN Australia
- NAMS Netherlands
- Employees
- IREN N/A
- NAMS N/A
- Industry
- IREN EDP Services
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- IREN Technology
- NAMS Health Care
- Exchange
- IREN Nasdaq
- NAMS Nasdaq
- Market Cap
- IREN 2.2B
- NAMS 2.2B
- IPO Year
- IREN 2021
- NAMS N/A
- Fundamental
- Price
- IREN $8.73
- NAMS $18.93
- Analyst Decision
- IREN Strong Buy
- NAMS Strong Buy
- Analyst Count
- IREN 11
- NAMS 6
- Target Price
- IREN $19.20
- NAMS $42.83
- AVG Volume (30 Days)
- IREN 15.9M
- NAMS 689.2K
- Earning Date
- IREN 05-14-2025
- NAMS 05-08-2025
- Dividend Yield
- IREN N/A
- NAMS N/A
- EPS Growth
- IREN N/A
- NAMS N/A
- EPS
- IREN N/A
- NAMS N/A
- Revenue
- IREN $377,821,000.00
- NAMS $47,140,000.00
- Revenue This Year
- IREN $183.79
- NAMS N/A
- Revenue Next Year
- IREN $80.18
- NAMS N/A
- P/E Ratio
- IREN N/A
- NAMS N/A
- Revenue Growth
- IREN 128.24
- NAMS 586.97
- 52 Week Low
- IREN $5.13
- NAMS $14.06
- 52 Week High
- IREN $15.92
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- IREN 61.53
- NAMS 54.33
- Support Level
- IREN $8.28
- NAMS $16.95
- Resistance Level
- IREN $9.43
- NAMS $19.58
- Average True Range (ATR)
- IREN 0.52
- NAMS 0.96
- MACD
- IREN -0.00
- NAMS -0.03
- Stochastic Oscillator
- IREN 59.48
- NAMS 76.20
About IREN Iris Energy Limited
IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.